NDA 211635 · Neurelis INC
Valtoco
Diazepam · Nasal · Benzodiazepine
OrphanLast checked: Nov 19, 2026Latest source record: Jun 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jan 10, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
118
16 Phase 3, 6 recruiting
FAERS reports
90,834
77,085 serious, 20,903 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.1) ] . The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes....
What it is approved for
From the label in effect Jun 3, 2026.
VALTOCO ® is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. VALTOCO is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. ( 1 )
Mechanism: The exact mechanism of action for diazepam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 15, 2025 Supplement 10 · Efficacy OrphanLetterLabel
- Jan 10, 2020 Original approval · Type 3 - New Dosage Form OrphanLabelLetterReview
3 products under this application
- VALTOCO · DIAZEPAM 7.5MG/SPRAY · SPRAY, NASAL · Prescription
- VALTOCO · DIAZEPAM 10MG/SPRAY · SPRAY, NASAL · Prescription
- VALTOCO · DIAZEPAM 5MG/SPRAY · SPRAY, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Diazepam" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral VertigoPivotal-lookingStatus unknown
University of MonastirAcademic, hospital or other
NCT06293989 · 1,000 participants (planned) · Start May 1, 2024 · Primary completion Dec 30, 2025
Drug: Diazepam 5mg; Diazepam 10 mg and 1 more · For: Vertigo, Peripheral
- Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in AsthmaPivotal-lookingCompleted
Oriel TherapeuticsIndustry
NCT02260492 · 879 participants · Start Sep 2014 · Primary completion May 2015
Drug: OT329 (combination of fluticasone propionate and salmeterol xinafoate); Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate) and 1 more · For: Asthma
Sites: Goodyear, Arizona; Tempe, Arizona; Anaheim, California · 47 sites in all
- Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)Pivotal-lookingCompleted
Avanti AnesthesiaAcademic, hospital or other
NCT03653520 · 651 participants · Start Jun 28, 2017 · Primary completion Nov 2, 2017
Drug: Diazepam; Tramadol and 2 more · For: Cataract
Sites: Houston, Texas
- Therapeutic Drug Monitoring of Anxiolytics in ChildrenStatus unknown
Wei ZhaoAcademic, hospital or other
NCT03960671 · 500 participants (planned) · Start Aug 1, 2018 · Primary completion Dec 31, 2022
Drug: Midazolam/diazepam/propofol · For: Anxiolytics
Sites: Ji'nan, China
- Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)Pivotal-lookingCompleted
McMaster UniversityAcademic, hospital or other
NCT03053869 · 480 participants · Start Apr 1, 2017 · Primary completion Sep 30, 2018
Drug: Benzodiazepine - limited use strategy; Benzodiazepine - Ad libitum strategy · For: Post-operative Delirium
Sites: Winnipeg, Canada; Hamilton, Canada
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Diazepam at the Active Phase of LaborPivotal-lookingStatus unknown
Navy General Hospital, BeijingAcademic, hospital or other
NCT02232035 · 400 participants (planned) · Start Sep 2014 · Primary completion Sep 2015
Drug: normal saline/diazepam at the active phase of labor · For: Pain; Prolonged Labour
Sites: Beijing, China
- Intranasal Midazolam Versus Rectal Diazepam for Treatment of SeizuresPivotal-lookingCompleted
University of UtahAcademic, hospital or other
NCT00326612 · 358 participants · Start Jun 2006 · Primary completion Dec 2008
Drug: Midazolam; Diazepam · For: Seizures
Sites: Salt Lake City, Utah
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxicity to various agents9,224
- drug abuse6,198
- drug ineffective5,161
- nausea4,223
- drug interaction3,890
- completed suicide3,880
- fatigue3,865
- somnolence3,697
- off label use3,647
- death3,415
- anxiety3,398
- headache3,292
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,140 |
| 2005 | 1,344 |
| 2006 | 1,170 |
| 2007 | 1,233 |
| 2008 | 1,797 |
| 2009 | 1,793 |
| 2010 | 2,345 |
| 2011 | 2,776 |
| 2012 | 3,252 |
| 2013 | 3,740 |
| 2014 | 3,766 |
| 2015 | 4,657 |
| 2016 | 5,306 |
| 2017 | 5,529 |
| 2018 | 6,524 |
| 2019 | 7,146 |
| 2020 | 6,752 |
| 2021 | 5,754 |
| 2022 | 5,062 |
| 2023 | 4,948 |
| 2024 | 5,314 |
| 2025 | 5,358 |
| 2026 | 4,117 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Valtoco (Diazepam)
2024 spending
$24.4M
Beneficiaries
9,366
20,987 claims
Per beneficiary
$2,604
$354.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,303,028 |
| 2021 | $5,591,384 |
| 2022 | $10,355,205 |
| 2023 | $17,228,355 |
| 2024 | $24,386,030 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study.
Tarquinio D, Wheless JW, Segal EB, et al. · J Child Neurol 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Diazepam modulates hippocampal CA1 functional connectivity in people at clinical high-risk for psychosis.
Livingston NR, Kiemes A, O'Daly O, et al. · Psychol Med 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Anticonvulsant therapy for status epilepticus.
Prasad M, Krishnan PR, Sequeira R, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Anticonvulsant therapy for status epilepticus.
Prasad K, Al-Roomi K, Krishnan PR, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Consistent safety and tolerability of Valtoco® (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study.
Miller I, Wheless JW, Hogan RE, et al. · Epilepsia Open 2021 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study.
Sperling MR, Wheless JW, Hogan RE, et al. · Epilepsia 2022 · Clinical Trial, Phase III
Sponsor: Neurelis INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.